Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 38 results:
Συντάκτης Τίτλος Τύπος [ Έτος] Φίλτρα: Keyword is Cholesterol, LDL [Clear All Filters]
Bone Health in Patients with Dyslipidemias: An Underestimated Aspect..
Int J Mol Sci. 23(3),
(2022). Lipoprotein(a) Reduction in Persons with Cardiovascular Disease..
N Engl J Med. 382(21), e65.
(2020). Increased High-Density Lipoprotein Levels Associated with Age-Related Macular Degeneration: Evidence from the EYE-RISK and European Eye Epidemiology Consortia..
Ophthalmology. 126(3), 393-406.
(2019). Management of dyslipidaemias in the elderly population-A narrative review..
Maturitas. 124, 93-99.
(2019).
(2019). The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins..
Curr Pharm Des. 23(10), 1477-1483.
(2017). Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes..
J Am Heart Assoc. 6(11),
(2017). Novel treatment options for the management of heterozygous familial hypercholesterolemia..
Expert Rev Clin Pharmacol. 10(12), 1375-1381.
(2017). Prognostic significance of major lipids in patients with acute ischemic stroke..
Metab Brain Dis. 32(2), 395-400.
(2017). The Role of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in the Management of Dyslipidemia..
Curr Pharm Des. 23(10), 1495-1499.
(2017). Lipoprotein(a) in postmenopausal women: assessment of cardiovascular risk and therapeutic options..
Int J Clin Pract. 70(12), 967-977.
(2016). Unresolved issues in lipid-lowering treatment..
Panminerva Med. 58(2), 191-5.
(2016). High-intensity statin therapy and regression of coronary atherosclerosis in patients with diabetes mellitus..
J Diabetes Complications. 29(1), 142-5.
(2015). Achieving lipid targets in primary care settings..
Curr Med Res Opin. 30(10), 1971-4.
(2014). Effects of lipid-lowering agents on inflammation, haemostasis and blood pressure..
Curr Pharm Des. 20(40), 6306-13.
(2014). Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients..
Curr Med Res Opin. 29(7), 791-2.
(2013). Adipokines: a novel link between adiposity and carotid plaque vulnerability..
Eur J Clin Invest. 42(12), 1278-86.
(2012). Apelin levels in normal pregnancy..
Clin Endocrinol (Oxf). 75(3), 367-71.
(2011). Association between the changes in renal function and serum uric acid levels during multifactorial intervention and clinical outcome in patients with metabolic syndrome. A post hoc analysis of the ATTEMPT study..
Curr Med Res Opin. 27(8), 1659-68.
(2011). The DEFINE study: a bright future for CETP inhibitors?.
Expert Opin Investig Drugs. 20(3), 311-4.
(2011). Effect of a plant stanol ester-containing spread, placebo spread, or Mediterranean diet on estimated cardiovascular risk and lipid, inflammatory and haemostatic factors..
Nutr Metab Cardiovasc Dis. 21(3), 213-21.
(2011). Efficacy and safety of long-term ezetimibe/simvastatin treatment in patients with familial hypercholesterolemia..
Int Angiol. 30(3), 295; author reply 296.
(2011). Ezetimibe and low density lipoprotein subfractions: an ongoing debate..
Curr Med Res Opin. 27(3), 693-5.
(2011). Oxidized low-density lipoprotein and adiponectin levels in pregnancy..
Gynecol Endocrinol. 27(12), 1070-3.
(2011). Aggressive lipid-lowering is more effective than moderate lipid-lowering treatment in carotid plaque stabilization..
J Vasc Surg. 51(1), 114-21.
(2010).